EA202190197A1 - Лечение язвенного колита с помощью бразикумаба - Google Patents
Лечение язвенного колита с помощью бразикумабаInfo
- Publication number
- EA202190197A1 EA202190197A1 EA202190197A EA202190197A EA202190197A1 EA 202190197 A1 EA202190197 A1 EA 202190197A1 EA 202190197 A EA202190197 A EA 202190197A EA 202190197 A EA202190197 A EA 202190197A EA 202190197 A1 EA202190197 A1 EA 202190197A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- brazikumab
- ulcer
- products
- suppress
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697939P | 2018-07-13 | 2018-07-13 | |
| PCT/IB2019/000720 WO2020012244A2 (en) | 2018-07-13 | 2019-07-11 | Treating ulcerative colitis with brazikumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190197A1 true EA202190197A1 (ru) | 2021-04-26 |
Family
ID=68072845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190197A EA202190197A1 (ru) | 2018-07-13 | 2019-07-11 | Лечение язвенного колита с помощью бразикумаба |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210277105A1 (enExample) |
| EP (1) | EP3820897A2 (enExample) |
| JP (1) | JP2021532176A (enExample) |
| KR (1) | KR20210032441A (enExample) |
| CN (1) | CN112689643A (enExample) |
| AU (1) | AU2019300491A1 (enExample) |
| CA (1) | CA3105598A1 (enExample) |
| EA (1) | EA202190197A1 (enExample) |
| IL (1) | IL279917A (enExample) |
| SG (1) | SG11202100185VA (enExample) |
| WO (1) | WO2020012244A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CN111718414B (zh) * | 2020-06-12 | 2021-03-02 | 江苏荃信生物医药有限公司 | 抗人白介素23单克隆抗体及其应用 |
| AU2023383916A1 (en) * | 2022-11-22 | 2025-07-10 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| WO2025170982A2 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ZA986596B (en) | 1997-07-25 | 1999-02-08 | Schering Corp | Mammalian cytokine related reagents |
| SI2452694T1 (sl) | 2005-06-30 | 2019-05-31 | Janssen Biotech, Inc. | Protitelesa proti-IL-23, sestavki in postopki uporabe |
| DE602006015830D1 (de) | 2005-08-25 | 2010-09-09 | Lilly Co Eli | Anti-il-23-antikörper |
| PT1931710T (pt) | 2005-08-31 | 2017-03-28 | Merck Sharp & Dohme | Anticorpos anti-il-23 manipulados |
| HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-IL-23 antibodies, preparations, methods and applications |
| US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
| ES2708988T3 (es) | 2007-02-23 | 2019-04-12 | Merck Sharp & Dohme | Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética |
| JP2010518858A (ja) | 2007-02-23 | 2010-06-03 | シェーリング コーポレイション | 操作された抗−ｉｌ−２３ｐ１９抗体 |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| EP2331078B1 (en) | 2008-08-27 | 2012-09-19 | Merck Sharp & Dohme Corp. | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| US20120128689A1 (en) | 2009-04-01 | 2012-05-24 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| US20120264917A1 (en) | 2009-05-27 | 2012-10-18 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| JO3244B1 (ar) * | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| PH12012501364A1 (en) | 2010-01-15 | 2012-10-22 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
| WO2012009760A1 (en) | 2010-07-20 | 2012-01-26 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| MX2019000046A (es) | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anticuerpos anti-il-23. |
| SG11201507483PA (en) * | 2013-03-15 | 2015-10-29 | Amgen Inc | Methods for treating crohn's disease using an anti-il23 antibody |
-
2019
- 2019-07-11 CN CN201980046566.9A patent/CN112689643A/zh active Pending
- 2019-07-11 US US17/259,448 patent/US20210277105A1/en not_active Abandoned
- 2019-07-11 CA CA3105598A patent/CA3105598A1/en active Pending
- 2019-07-11 EA EA202190197A patent/EA202190197A1/ru unknown
- 2019-07-11 JP JP2021524129A patent/JP2021532176A/ja active Pending
- 2019-07-11 WO PCT/IB2019/000720 patent/WO2020012244A2/en not_active Ceased
- 2019-07-11 KR KR1020217004216A patent/KR20210032441A/ko not_active Ceased
- 2019-07-11 SG SG11202100185VA patent/SG11202100185VA/en unknown
- 2019-07-11 AU AU2019300491A patent/AU2019300491A1/en not_active Abandoned
- 2019-07-11 EP EP19779090.0A patent/EP3820897A2/en not_active Withdrawn
-
2021
- 2021-01-03 IL IL279917A patent/IL279917A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020012244A2 (en) | 2020-01-16 |
| SG11202100185VA (en) | 2021-02-25 |
| EP3820897A2 (en) | 2021-05-19 |
| CN112689643A (zh) | 2021-04-20 |
| IL279917A (en) | 2021-03-01 |
| AU2019300491A1 (en) | 2021-03-04 |
| US20210277105A1 (en) | 2021-09-09 |
| JP2021532176A (ja) | 2021-11-25 |
| WO2020012244A3 (en) | 2020-06-04 |
| KR20210032441A (ko) | 2021-03-24 |
| CA3105598A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| ZA201905488B (en) | Tigit- and light-based chimeric proteins | |
| PH12020551710A1 (en) | Anti-hla-g antibodies and use thereof | |
| ZA201903327B (en) | Compositions and methods for the induction of cd8+ t¿cells | |
| EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| PH12020500576A1 (en) | Method of treating cancers with antagonistic anti-pd-1 antibodies | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201791775A1 (ru) | Цистеиновая протеаза | |
| EA202091989A1 (ru) | Способы лечения язвенного колита | |
| EA202190197A1 (ru) | Лечение язвенного колита с помощью бразикумаба | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| AR105335A1 (es) | Anticuerpos monoclonales anti-sortilina |